GlassScriptPhysician profile
John Clyde Rickabaugh
NPI 1396722534
$1,962.34
in general payments reported to CMS, 2019-2025
26 companies · $382 in 2025
The $382 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,072 · 2020: $278 · 2021: $87.00 · 2022: $13.87 · 2023: $21.30 · 2024: $109 · 2025: $382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $512.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $221.81 | 2019-2025 | |
| Glaxosmithkline, LLC. | $218.23 | 2019-2025 | Trelegy Ellipta |
| Novo Nordisk INC | $200.98 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $187.18 | 2019-2025 | Farxiga |
| Astellas Pharma US INC | $125.75 | 2019 | |
| Novartis Pharmaceuticals Corporation | $109.58 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $107.32 | 2019-2025 | Xifaxan |
| Amgen INC. | $103.68 | 2019-2025 | Repatha, Otezla |
| Abbvie INC. | $94.87 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $82.73 | 2019-2020 | |
| Amarin Pharma, INC. | $68.31 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $56.19 | 2019 | |
| Lilly USA, LLC | $55.46 | 2019-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.00 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $42.19 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $33.16 | 2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $26.01 | 2019 | |
| Antares Pharma, INC. | $25.19 | 2019 | |
| Phathom Pharmaceuticals, INC. | $24.12 | 2024 | Voquezna |
| Sumitomo Pharma America, INC. | $24.06 | 2025 | Gemtesa |
| Tolmar, INC. | $22.85 | 2025 | Jatenzo |
| Boston Scientific Corporation | $19.90 | 2020 | |
| Dexcom, INC. | $18.45 | 2025 | Dexcom G6 Transmitter |
| Ironwood Pharmaceuticals, INC | $14.96 | 2020 | |
| Arbor Pharmaceuticals, INC. | $13.45 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.91 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Rickabaugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.